Active Biotech Regains Rights to Laquinimod from Teva, Plans to Continue Work on Potential MS Oral Therapy
Juha-Matti Savola's research works | Teva Pharmaceutical Industries Ltd., Petah Tikva (TEVA) and other places
Multiple Sclerosis Research: Will Teva and Biogen Come together for the sake of DMF, laquinimod polypill
FDA Marks Change in Clinical Test Dose of MS Therapy, Laquinimod
Molecules | Free Full-Text | Laquinimod Modulates Human Astrocyte Function and Dampens Astrocyte-Induced Neurotoxicity during Inflammation
Laquinimod - an overview | ScienceDirect Topics
Laquinimod | C19H17ClN2O3 | CID 54677946 - PubChem
AhR activators - friend or foe? - Hypha Discovery Blogs
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
Investigational Laquinimod Demonstrates Its Potential as a New Oral Treatment For RRMS | Fierce Pharma
Laquinimod - Wikipedia
Multiple Sclerosis Clinical Trial Update: Laquinimod
A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis | Neurology
laquinimod
A Broad Look At Teva's Pipeline (NYSE:TEVA) | Seeking Alpha
Laquinimod - Wikipedia
Cells | Free Full-Text | Laquinimod Supports Remyelination in Non-Supportive Environments
Teva backs laquinimod for MS despite CHMP rejection - PMLiVE
Heart Incidents End Parts of Two Studies by Teva, Active Biotech - WSJ
Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells - Dobson - 2016 - Journal of Neurochemistry - Wiley Online Library
AhR activators - friend or foe? - Hypha Discovery Blogs
Teva Pharmaceuticals - Wikipedia
Teva hit with largest-ever fine under US anti-corruption act - PMLiVE
Active Biotech and Teva together in a Phase II clinical trial against Huntington's disease - Labiotech.eu
EuroBiotech Report—Teva dumps laquinimod, Gilead-Galapagos, GV-Evox, Abivax data and ProQR | Fierce Biotech
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
